Urokinase-Plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer

Cancer Research

Volumn 50, Issue 21, 1990, Pages 6827-6829

  Duffy, Michael J ^a   Reilly, David ^a   O'Sullivan, Cathriona ^b   O'Higgins, Niall ^c   Fennelly, James J ^a   Andreasen, Peter ^d  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b ST LUKE S HOSPITAL   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR; RADIOISOTOPE;

ARTICLE; BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TISSUE LEVEL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; FEMALE; FIBRINOLYTIC AGENTS; HUMAN; NEOPLASM RECURRENCE, LOCAL; PLASMINOGEN ACTIVATORS; PROGNOSIS; SUPPORT, NON-U.S. GOV'T; TUMOR MARKERS, BIOLOGICAL; URINARY PLASMINOGEN ACTIVATOR;

EID: 0025013834     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Duffy, M. J. Do proteases play a role in cancer invasion and metastasis? Eur. J. Cancer Clin Oncol., 23: 583–589, 1987.
2. Zucker, S. A critical appraisal of the role of proteolytic enzymes in cancer invasion: emphasis on tumor surface proteinases. Cancer Invest., 6: 219– 231, 1988.
3. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H.J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer (Phila.), 62: 531–533, 1988.
4. O'Grady, P., Lijnen, H. R., and Duffy, M. J. Multiple forms of plasminogen activator in human breast tumours. Cancer Res., 45: 6216–6218, 1985.
5. Lund, L. R., Georg, B., Nielsen, L. S., Mayer, M., Dano, K., and Andreasen, P. A. Plasminogen activator inhibitor type 1: cell specific and differentiation-induced expression and regulation in human cell lines, as determined by enzyme-linked immunosorbent assay. Mol. Cell. Endocrinol., 60: 43–53, 1988.
6. Grondahl-Hansen, J., Agerlin, N., Munkholm-Larsen, P., Bach, F., Nielsen, L. S., Dombernowsky, P., and Dano, K. Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. J. Lab. Clin. Med., Ill: 42–51, 1988.
7. Andreasen, P. A., Nielsen, L. S., Kristensen, P., Grondahl-Hansen, J., Skriver, L., and Dane, K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator but not its proenzyme. J. Biol. Chem., 261: 7644–7651, 1986.
8. Duffy, M. J., O'Connell, M., O'Sullivan, F., McKenna, B., Allen, M. A., and McDonnell, L. CEA-like material in cytosols from human breast carcinomas. Cancer (Phila.), 51: 121–123, 1983.
9. Jänicke, F., Schmitt, M., Ulm, K., Gössner, W., and Graeff, H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet, 2: 1049, 1989.
10. Jänicke, F., Schmitt, M., Hafter, R., Hollrieder, A., Babic, R., Ulm, K., Gössner, W., and Graeff, H. Urokinase-type plasminogen activator (U-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis, 4: 69–78, 1990.
11. Thorpe, S. M., Rochefort, H., Garcia, M., Freiss, G., Christensen, I. J., Khalaf, S., Paulucci, F., Pau, B., Rasmussen, B. B., and Rose, C. Association between high concentrations of A/r 52,000 Cathepsin D and poor prognosis in primary breast cancer. Cancer Res., 49: 6008–6014, 1989.
12. Spy ratos, F., Brouillet, J-P., Defrenne, A., Hacene, K., Rouesse. J., Maude-londe, T., Brünett, M., Andrieu, C., Desplaces, A., and Rochefort, H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet, 2: 1115–1118, 1989.
13. Tandon, A. K., Clark, G. M., Chamness, G. C., Chirgwin, J. M., and McGuire, W. L. Cathepsin D and prognosis in breast cancer. N. Engl. J. Med., 322: 297–302, 1990.
14. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell, 35: 611–619, 1983.
15. Duffy, M. J., O'Grady, P., Devaney, D., O'Siorain, L., Fennelly, J. J., and Lijnen, H. R. Tissue-type plasminogen activator, a new prognostic marker in breast cancer. Cancer Res., 48: 1348–1349, 1988.
16. Edwards, D. P., Chamness, G. C., and McGuire, W. L. Estrogen and progesterone receptor proteins in breast cancer. Biochim. Biophys. Acta, 560:457–486, 1979.
17. Sainsbury, J., Farndon, J. R., Needham, G. K., Malcolm, A. J., and Harris, A. L. Epidermal-growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1: 1398–1402, 1987.
18. Slamon, J. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177–182, 1987.